MeiraGTx Holdings plc Ordinary Shares
MGTXMeiraGTx Holdings plc is a clinical-stage gene therapy company focused on developing treatments for rare and serious diseases. Based in the UK, the company specializes in creating advanced gene therapy products using proprietary platforms to deliver potentially curative therapies for conditions such as neurological, ophthalmic, and infectious diseases.
Company News
MeiraGTx Chief Scientific Officer Stuart Naylor sold 27,659 shares (4% of holdings) for $409,000 on July 7, 2026, under a pre-scheduled Rule 10b5-1 trading plan adopted in December 2025. The sale appears routine following an 89% one-year stock surge and likely reflects portfolio diversification rather than lack of confidence. The company remains ...
MeiraGTx reacquired bota-vec, a treatment for X-linked retinitis pigmentosa (XLRP), from Johnson & Johnson for a $25 million upfront payment. The company raised $100 million through a share offering and plans to expedite regulatory filings for U.S. and EU approval with a potential 2027 launch. Three-year data from its xerostomia treatment showed ...
MeiraGTx has entered into an asset purchase agreement with Johnson & Johnson to acquire all interests in botaretigene sparoparvovec (bota-vec) for treating X-linked retinitis pigmentosa. The company will pay $25 million upfront plus regulatory and commercial milestones, with royalties on global net sales. Phase 3 LUMEOS study data showed clinical...
Eli Lilly signed a strategic collaboration with MeiraGTx for ophthalmology gene therapy, granting worldwide exclusive rights to AAV-AIPL1 program for Leber congenital amaurosis 4, with an upfront payment of $75 million and potential milestone payments over $400 million.
MeiraGTx reported Q2 2025 results with significant revenue growth but missed analyst estimates. The company advanced several gene therapy programs, secured key partnerships, and maintained strong manufacturing capabilities despite ongoing financial challenges.
